Literature DB >> 33927124

Characteristics and Outcomes of Children With Cystic Fibrosis Hospitalized With Cirrhosis in the United States.

Christina Thornton1, Ranjani Somayaji1,2,3, Michael Parkins1,2, Mark G Swain1, Kathleen J Ramos4, Christopher H Goss4, Abdel A Shaheen1,2,3.   

Abstract

INTRODUCTION: To describe the characteristics and outcomes of children with cystic fibrosis (CF) hospitalized with cirrhosis in the United States.
METHODS: We conducted a population-based cohort study of hospitalizations among children with CF using the 2016 Kid's Inpatient Database.
RESULTS: In total, 9,615 admissions were analyzed. Diagnosis of cirrhosis was present in 509 (5.3%) and was significantly associated with increased mortality, length of stay, and hospital charges compared with those without cirrhosis. Hepatic encephalopathy was significantly associated with death in children with cirrhosis. DISCUSSION: Future interventions should be designed to support children with CF who have cirrhosis to improve clinical outcomes.
Copyright © 2021 by The American College of Gastroenterology.

Entities:  

Mesh:

Year:  2021        PMID: 33927124      PMCID: PMC8484050          DOI: 10.14309/ajg.0000000000001275

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   12.045


  13 in total

1.  Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.

Authors:  Guadalupe Garcia-Tsao; Arun J Sanyal; Norman D Grace; William Carey
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

2.  Obliterative Portal Venopathy Without Cirrhosis Is Prevalent in Pediatric Cystic Fibrosis Liver Disease With Portal Hypertension.

Authors:  Hao Wu; Megan Vu; Sadhna Dhingra; Ruth Ackah; John A Goss; Abbas Rana; Norma Quintanilla; Kalyani Patel; Daniel H Leung
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-04       Impact factor: 11.382

Review 3.  Strategies for management of pediatric cystic fibrosis liver disease.

Authors:  Molly Bozic; Jean Molleston
Journal:  Clin Liver Dis (Hoboken)       Date:  2013-10-30

Review 4.  Hepatic Manifestations of Cystic Fibrosis.

Authors:  Sasan Sakiani; David E Kleiner; Theo Heller; Christopher Koh
Journal:  Clin Liver Dis       Date:  2019-02-21       Impact factor: 6.126

Review 5.  Liver disease in patients with cystic fibrosis.

Authors:  Natasha Kamal; Pallavi Surana; Christopher Koh
Journal:  Curr Opin Gastroenterol       Date:  2018-05       Impact factor: 3.287

Review 6.  Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations.

Authors:  Oren Ledder; Wolfram Haller; Richard Tl Couper; Peter Lewindon; Mark Oliver
Journal:  J Gastroenterol Hepatol       Date:  2014-12       Impact factor: 4.029

7.  Epidemiology of liver disease in cystic fibrosis: a longitudinal study.

Authors:  Thierry Lamireau; Sylvie Monnereau; Steven Martin; Jacques-Edouard Marcotte; Maria Winnock; Fernando Alvarez
Journal:  J Hepatol       Date:  2004-12       Impact factor: 25.083

8.  Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data.

Authors:  Manuel Mendizabal; K Rajender Reddy; James Cassuto; Kim M Olthoff; Thomas W Faust; George A Makar; Elizabeth B Rand; Abraham Shaked; Peter L Abt
Journal:  Liver Transpl       Date:  2011-03       Impact factor: 5.799

9.  Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome.

Authors:  Carla Colombo; Pier Maria Battezzati; Andrea Crosignani; Alberto Morabito; Diana Costantini; Rita Padoan; Annamaria Giunta
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

10.  Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study.

Authors:  Lauren Lapointe-Shaw; Firass Georgie; David Carlone; Orlando Cerocchi; Hannah Chung; Yvonne Dewit; Jordan J Feld; Laura Holder; Jeffrey C Kwong; Beate Sander; Jennifer A Flemming
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.